Scholarlink

<p>Peptide-activated G protein-coupled receptors (GPCRs) play crucial roles in numerous diseases, but remain difficult therapeutic targets due to the challenges in developing small-molecule drugs. Here, we explore structure-based strategies to identify small-molecule agonists of neurotensin (NTS) receptors, which hold promise for developing non-opioid analgesics. Chemical libraries of drug-like molecules are first designed based on a receptor-peptide complex, and then 14.5 million compounds are computationally docked to the orthosteric binding site of the NTS<sub>1</sub> receptor. A set of 39 top-ranked compounds is synthesized, and seven of these are experimentally confirmed to activate the NTS<sub>1</sub> receptor. Structure-guided optimization yields NTS<sub>1</sub> ligands with signaling signatures distinct from the endogenous peptide, and these compounds also exhibit high affinity for the NTS<sub>2</sub> receptor. High-resolution crystal structures of two agonists bound to the NTS<sub>1</sub> receptor confirm predicted binding modes and reveal key determinants of activation. In vivo, the compounds produce robust antinociception in rodents without inducing hypotension, consistent with a contribution of NTS<sub>2</sub> receptor activity. To facilitate broader application of our virtual screening approach to peptide-binding GPCRs, we provide access to tailored chemical libraries containing billions of readily synthesizable compounds.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Docking of virtual libraries identifies small-molecule agonists of neurotensin receptors with analgesic activity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Nicolas Panel,
  • Duy Duc Vo,
  • Harald Hübner,
  • Mattia Deluigi,
  • Szymon Pach,
  • Félix Bélair,
  • Dorothee Weikert,
  • Christoph Klenk,
  • Mark Hilge,
  • Niharika Shiva,
  • Isabelle Brochu,
  • Jean-Michel Longpré,
  • Frida Bällgren,
  • Aljona Saleh,
  • Huabin Hu,
  • Jon Kapla,
  • Stefanie Kampen,
  • Israel Cabeza de Vaca,
  • Jan Kihlberg,
  • Nina Wettschureck,
  • Philippe Sarret,
  • Andreas Plückthun,
  • Peter Gmeiner,
  • Jens Carlsson

摘要

Peptide-activated G protein-coupled receptors (GPCRs) play crucial roles in numerous diseases, but remain difficult therapeutic targets due to the challenges in developing small-molecule drugs. Here, we explore structure-based strategies to identify small-molecule agonists of neurotensin (NTS) receptors, which hold promise for developing non-opioid analgesics. Chemical libraries of drug-like molecules are first designed based on a receptor-peptide complex, and then 14.5 million compounds are computationally docked to the orthosteric binding site of the NTS1 receptor. A set of 39 top-ranked compounds is synthesized, and seven of these are experimentally confirmed to activate the NTS1 receptor. Structure-guided optimization yields NTS1 ligands with signaling signatures distinct from the endogenous peptide, and these compounds also exhibit high affinity for the NTS2 receptor. High-resolution crystal structures of two agonists bound to the NTS1 receptor confirm predicted binding modes and reveal key determinants of activation. In vivo, the compounds produce robust antinociception in rodents without inducing hypotension, consistent with a contribution of NTS2 receptor activity. To facilitate broader application of our virtual screening approach to peptide-binding GPCRs, we provide access to tailored chemical libraries containing billions of readily synthesizable compounds.